Faron Pharmaceuticals Oy
LSE:FARN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Faron Pharmaceuticals Oy
LSE:FARN
|
FI |
|
C
|
CanAsia Energy Corp
OTC:CECAF
|
CA |
|
Washington H. Soul Pattinson and Company Ltd
ASX:SOL
|
AU |
|
L
|
London City Equities Ltd
ASX:LCE
|
AU |
|
Boustead Singapore Ltd
SGX:F9D
|
SG |
|
H
|
Host Hotels and Resorts, Inc
F:HMT
|
US |
|
K
|
KC Feed Co Ltd
KOSDAQ:025880
|
KR |
|
D
|
DSK Co Ltd
KOSDAQ:109740
|
KR |
|
I
|
IBKS No.22 Special Purpose Acquisition Co
KOSDAQ:448760
|
KR |
Intrinsic Value
Is FARN undervalued or overvalued?
See the intrinsic value estimate for Faron Pharmaceuticals Oy and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
FARN looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with FARN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Faron Pharmaceuticals Oy Does
Faron Pharmaceuticals is a drug development company focused on medicines that change how the immune system behaves in cancer and severe inflammation. Its main work is to discover and test new drug candidates, especially bexmarilimab, an immunotherapy aimed at helping the body’s own defenses attack tumors. The company is not a mass-market drug seller; it is a research-stage biotech trying to turn lab findings into approved medicines.
- Headquarters
- Finland FI
- Employees
- 33
- IPO date
- Nov 17, 2015
Earnings Waterfall
Faron Pharmaceuticals Oy
The intrinsic value for Faron Pharmaceuticals Oy (FARN) under the Base Case is hidden GBX.
Compared with the current market price of 32.5 GBX, the stock appears hidden.